Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
New York, NY – July 14, 2025 – Sun Pharmaceutical Industries Ltd. (NYSE: SUNP) is pleased to announce the U.S. launch of LEQSELVI™ (deuruxolitinib), a significant advancement in the treatment of severe alopecia areata. This innovative oral medication is now available to eligible adult patients across the United States, offering a new therapeutic option for those affected by this challenging autoimmune condition.
Alopecia areata is a condition characterized by hair loss, often in patches, which can occur on the scalp, face, and other areas of the body. In severe cases, it can lead to complete scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The impact of severe alopecia areata can extend beyond physical symptoms, significantly affecting a patient’s self-esteem and overall quality of life.
LEQSELVI™ (deuruxolitinib) represents a new oral Janus kinase (JAK) inhibitor. By targeting specific JAK pathways involved in the inflammatory response, deuruxolitinib aims to modulate the immune system’s attack on hair follicles, thereby promoting hair regrowth. The U.S. Food and Drug Administration (FDA) approval of LEQSELVI™ was based on robust clinical trial data demonstrating its efficacy and safety profile in treating adults with severe alopecia areata.
“We are incredibly proud to bring LEQSELVI™ to patients in the United States,” said [Name and Title of Sun Pharma Representative, if available from the source, otherwise omit or use a placeholder like “a spokesperson for Sun Pharma”]. “Alopecia areata can be a deeply distressing condition, and our goal is to provide meaningful treatment options that can help improve the lives of those who are struggling with severe hair loss. The launch of LEQSELVI™ underscores our commitment to addressing unmet medical needs in dermatology and bringing innovative therapies to market.”
The availability of LEQSELVI™ is a welcome development for the alopecia areata community, offering a much-anticipated oral treatment option. Patients and healthcare providers can now explore this new therapeutic pathway for managing severe alopecia areata.
For further information regarding LEQSELVI™ and its availability, patients and healthcare professionals are encouraged to consult with their physicians and refer to the official product information.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Policy Public Interest published ‘Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata’ at 2025-07-14 11:27. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.